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I. Introduction  
In October 2004, a resident of Weston, Massachusetts contacted the Massachusetts Department 
of Public Health (MDPH), Center for Environmental Health (CEH) regarding concerns over a 
suspected increase in the incidence of brain cancer among children in Weston.  Specifically, the 
resident reported that four school-aged children in Weston had been diagnosed with brain cancer 
since 2000 and expressed concerns over whether this may represent an atypical pattern or 
possibly be related to a common environmental factor.  In addition, the resident also reported a 
child who had been diagnosed with brain cancer but lived in Wayland (on the Wayland-Weston 
border) in somewhat close proximity to the former Dow Chemical Site.  In response to these 
concerns, the Community Assessment Program (CAP), a division within the CEH, reviewed the 
incidence of brain cancer in the towns of Weston and Wayland with particular attention to the 
incidence of this cancer type among children (i.e., ages 0-19). 
 
II. Methods  
To determine whether an atypical pattern of brain cancer exists among children in Weston and 
Wayland, the CAP reviewed Massachusetts Cancer Registry (MCR) data files for residents of 
these two towns who had been diagnosed with brain cancer during 1995-present.  [Coding for 
this cancer type follows the International Classification of Diseases for Oncology (ICD-O) 
system.  See Appendix A for the incidence coding definition used in this report for this cancer 
type.]  The MCR, a division within the MDPH Center for Health Information, Statistics, 
Research and Evaluation, is a population-based surveillance system that has been monitoring 
cancer incidence in the Commonwealth since 1982.  All new diagnoses of cancer among 
Massachusetts residents are required by law to be reported to the MCR within six months of the 
date of diagnosis (M.G.L. c.111. s 111b).  This information is kept in a confidential database.  
Data are collected on a daily basis and are reviewed for accuracy and completeness on an annual 
basis.  This process corrects misclassification of data (e.g., city/town misassignment) and deletes 
duplicate case reports.  Once these steps are finished, the data for that year are considered 
“complete.”  At the initiation of this investigation, complete data records included diagnoses that 
occurred from 1/1/1982-12/31/2001.  Due to the volume of information received by the MCR, 
the large number of reporting facilities, and the six-month period between diagnosis and required 
reporting, the most current registry data that are complete will inherently be a minimum of two 
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years prior to the current date.  The 7-year period from 1995-2001 constitutes the time period for 
which the most recent and complete cancer incidence data were available from the MCR at the 
time this investigation was initiated.1  This is an on-going surveillance system that collects 
reports on a daily basis, and thus, CAP staff conducted a qualitative review of case reports of 
diagnoses of brain cancer among residents of the towns of Weston and Wayland for more recent 
years (i.e., 2002-present).  While this type of evaluation does not allow for the calculation of a 
cancer rate for 2002-present, it can provide a qualitative review of cancer patterns in a given 
area.   
 
It is important to note that although some non-cancerous (i.e., benign) tumors of the brain are 
reported to the MCR, these cases are not included in the data summarized here.  Also, only 
primary site (original location in the body) cancers are included in the MCR.  Cancers that occur 
as the result of the metastasis or the spread of a primary site cancer to another location in the 
body are not considered separate cancers.  Therefore, this analysis includes only diagnoses of 
invasive (i.e., malignant) primary cancers of the brain. 
 
In order to determine whether cancer incidence in a community is occurring at a higher or lower 
rate than expected, a statistic called the standardized incidence ratio (SIR) is calculated using 
data from the MCR.  More specifically, the SIR is the number of observed cancer cases in a town 
(or census tract) divided by the number of expected cases based upon the population of the town 
(or census tract) and the state’s cancer rates.  An SIR greater than 100 indicates that more cancer 
diagnoses occurred than expected; an SIR less than 100 means that fewer diagnoses occurred 
than expected.  For example, an SIR of 150 is interpreted as 50 percent more cases than 
expected; an SIR of 90 indicates 10 percent fewer cases than expected.  When an SIR is 
statistically significant, as indicated in the table by an asterisk symbol (*), there is less than a 5% 
chance that the observed number of diagnoses is due to chance alone.  SIRs and 95% confidence 
intervals (CIs) are not calculated when the observed number of cases is less than five.  A more 
detailed explanation of SIRs and 95% CIs is provided in Appendix B.  
 
1 The data summarized here are drawn from data entered on MCR computer files before November 22, 2005.  The 
numbers presented may differ slightly from those published in previous or future reports, reflecting late reported 
cases, address corrections, or other changes based on subsequent details from reporting facilities. 
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Because accurate age group and gender specific population data are required to calculate SIRs, 
the census tract (CT) is the smallest geographic area for which cancer rates can be accurately 
calculated.  Specifically, census tracts are small, relatively permanent geographic entities within 
counties (or the statistical equivalents of counties) defined by a committee of local data users 
following Census Bureau guidelines.  CTs usually contain between 2,500 and 8,000 persons and 
are designed to be homogenous with respect to population characteristics.  According to the U.S. 
Census, the town of Weston is divided into two CTs, 3671 and 3672, as is the town of Wayland 
(CTs 3661 and 3662) (U.S. DOC, 2000).  The town boundaries and census tract locations for 
Weston and Wayland are illustrated in Figure 1.  SIRs were calculated for brain cancer for each 
town as a whole and for each CT for the time period 1995-2001.  As noted earlier, MCR data for 
the years 2002-present were not complete at the initiation of this investigation.  Therefore, they 
were not used to calculate incidence rates; however the information was reviewed qualitatively 
to determine if any geographic patterns might exist. 
 
In addition to calculating SIRs, place of residence at the time of diagnosis was mapped for each 
individual (e.g., adults and children) diagnosed with brain cancer in Weston and Wayland during 
the time period 1995-2005 using a computerized geographic information system (GIS) (ESRI, 
2004).  This allowed assignment of census tract location for each case as well as a qualitative 
evaluation of the spatial distribution of diagnoses at a smaller geographic level (i.e., 
neighborhoods) in order to determine the likelihood of a potential association with environmental 
factors (e.g. the former Dow Chemical site).  The geographic pattern was determined using a 
qualitative evaluation of the point pattern of individuals diagnosed with cancer to assess any 
possible concentrations of cases.  For confidentiality reasons, maps showing the location of 
individuals diagnosed with cancer cannot be provided.  However, a summary of this evaluation 
with any notable findings is presented in this report. 
 
III. Results 
Five children (four from the town of Weston and one in the town of Wayland) with a reported 
diagnosis of brain cancer were reported in the original request to the CEH for an investigation.  
Information about the five children was limited and varied for each child.  Full names were not 
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provided for any of the children; the last name of one child was listed in the letter.  Address at 
diagnosis was listed for three children and an approximate year of diagnosis was provided for 
four of the five children.  Following receipt of the original request, the CEH received the full 
names for two of the children from the resident who had made the request.  Requests for 
additional information on children diagnosed with brain cancer were also made to three Weston 
school nurses that the resident listed as potential sources of information.  The CEH also 
contacted the Weston Board of Health for reports of children with brain cancer that their office 
may have received.  No additional information was available from the Board of Health or the 
Weston school nurses.  
 
Based on the information provided by the resident, the CAP was able to confirm the diagnoses of 
three children in the MCR (three Weston residents).  All three children were reported to the 
MCR with a diagnosis of brain cancer (two were diagnosed in 1995-2001 and one was diagnosed 
during the 2002-present period).  Although MCR data were reviewed through the present time 
(November 2005), the CAP was unable to confirm a cancer diagnosis for two of the children 
reported to the CEH.  One possible reason for this may be a recent diagnosis of cancer that has 
not yet been reported to the MCR.  Another possibility is that these children were diagnosed 
before moving to Weston or Wayland.  Finally, it is also possible that these children may have 
actually been diagnosed with a pre-cancerous or non-cancerous condition (e.g., aplastic anemia) 
which would not be included in the MCR data files, or with another primary cancer type.  
Information reviewed from the MCR on all brain cancers (in adults and children) diagnosed in 
Weston and Wayland from 1995 to the present will be discussed later in this report.   
 
A. Brain Cancer Incidence in Weston 
During the time period of 1995-2001, two children (i.e., age 0-19) were diagnosed with brain 
cancer town-wide, while about one child would have been expected to be diagnosed with brain 
cancer in Weston.  Overall, the town-wide incidence of brain cancer (including children and 
adults) was statistically significantly elevated for the time period of 1995-2001.  A total of 15 
individuals were diagnosed with brain cancer while about six diagnoses would have been 
expected (SIR = 238, 95% CI = 133-392).  This elevation was due to an increase in females in 
the town of Weston.  Ten females were diagnosed with this cancer type while approximately 
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three cases were expected (SIR = 364, 95% CI = 174-670); this difference is statistically 
significant (see Table 1).   
 
The town of Weston is made up of two CTs, one that covers the northern section of town (CT 
3671) and the other encompasses the southern portion of town (CT 3672).  Both Weston CTs 
border Wayland CT 3662 (See Figure 1).  For the two children diagnosed during the 1995-2001 
time period, their residences at the time of diagnosis, as reported to the MCR, were determined 
to be in different census tracts in Weston.  During 1995-2001, CT 3672 experienced a 
statistically significant elevation in the overall (males and females combined) rate of brain cancer 
with 11 diagnoses observed and four diagnoses expected (SIR = 273, 95% CI = 136-489).  The 
overall elevation was due to a statistically significant increase in the incidence of brain cancer 
among females in CT 3672.  Seven females in this CT were diagnosed with brain cancer during 
this time period while approximately two cases were expected (SIR = 387, 95% CI = 155-797).  
Among females in CT 3671, three diagnoses of brain cancer were observed versus about one 
expected for this time period. 
 
  Table 1 - Brain Cancer Incidence in Weston, MA: 1995-2001 
Total Males Females  
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Town total 15 6.3 238* 133-392 5 3.6 140 45-328 10 2.7 364* 174-670 
CT 3671 4 2.3 NC NC 1 1.3 NC NC 3 0.9 NC NC 
CT 3672 11 4.0 273* 136-489 4 2.2 NC NC 7 1.8 387* 155-797 
Notes: Obs = observed; Exp = expected; 95% CI = 95% confidence interval;  
NC = not calculated; * = statistical significance 
 
B. Brain Cancer Incidence in Wayland  
Among children (i.e., age 0-19) in the town of Wayland, one child was diagnosed with brain 
cancer during the 1995-2001 time period, which is what would have been expected based on the 
statewide brain cancer experience for children.  Town-wide incidence of brain cancer, during this 
period, among males and females combined was slightly above the rate expected.  A total of nine 
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individuals were diagnosed with brain cancer while seven cases were expected (SIR = 129, 95% 
CI = 59-244) (See Table 2).  This elevation was not statistically significant. 
 
The town of Wayland has two CTs, one that covers the northern section of town (CT 3662) and 
the other encompasses the southern portion of town (CT 3661) (See Figure 1).  During 1995-
2001, two residents of CT 3661 (both male) were diagnosed with brain cancer while 
approximately three cases were expected.  For CT 3662, seven individuals were diagnosed with 
brain cancer while approximately four were expected.  However, the elevation was not 
statistically significant (See Table 2). 
 
Table 2 - Brain Cancer Incidence in Wayland, MA:  1995-2001 
Total Males Females  
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Town total 9 7.0 129 59-244 5 3.9 127 41-297 4 3.1 NC NC 
CT 3661 2 2.6 NC NC 2 1.4 NC NC 0 1.2 NC NC 
CT 3662 7 4.4 160 64-330 3 2.5 NC NC 4 1.8 NC NC 
Notes: Obs = observed; Exp = expected; 95% CI = 95% confidence interval;  
NC = not calculated; * = statistical significance 
 
 
C. Temporal Distribution of Brain Cancer in Weston and Wayland 
From 1995-present, a total of 20 individuals from the town of Weston have been reported to the 
MCR with a diagnosis of brain cancer.  This includes the 15 individuals diagnosed during 1995-
2001 (including two children ages 0-19) and five individuals (including one child) diagnosed in 
the 2002-present time period.  A total of 11 individuals from the town of Wayland have been 
reported to the MCR with a diagnosis of brain cancer from 1995-present.  This includes nine 
individuals diagnosed during 1995-2001 (including one child) and two individuals diagnosed in 
the 2002-present time period (including one child). 
 
Dates of diagnosis for residents of Wayland and Weston diagnosed with brain cancer were 
evaluated to assess any time trends that might be present since 1995.  The years of diagnosis for 
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each individual diagnosed with brain cancer in each of the two towns generally varied 
throughout the time period of 1995-present, thereby not indicating unusual temporal patterns.   
 
D. Geographic Distribution of Brain Cancer 
In addition to determining census tract-specific incidence ratios for brain cancer in the towns of 
Weston and Wayland, a qualitative evaluation of the spatial distribution of residents of Weston 
and Wayland diagnosed with brain cancer from 1995-present was conducted to assess any 
possible geographic concentration of diagnoses in specific neighborhoods within these two 
communities.   
 
Review of geographic distribution of Wayland and Weston residents diagnosed with brain cancer 
from 1995-present did not reveal any unusual spatial patterns or concentrations of individuals 
diagnosed with brain cancer within any census tract including in the area of South Wayland 
around the former Dow Chemical Site.  That is, the residence of individuals diagnosed with brain 
cancer did not appear spatially concentrated or “clustered” in any one area of the town.  In 
general, the geographic distribution of diagnoses closely matched the pattern of population 
density in Wayland and Weston.  
 
E. Review of Case Information 
Despite numerous scientific and medical investigations, and analyses, the causes of brain cancer 
are still largely unknown.  However, a few risk factors have been identified.  The most well-
established risk factor is exposure to ionizing radiation (e.g., from radiation therapy to the head 
and neck) (ACS, 2004a).  In addition, rare cases of brain cancer run in some families.  Some 
types have also been associated with certain rare genetic disorders, such as neurofibromatosis 
type 1, von Hippel-Lindau disease, and Li-Fraumeni syndrome (ACS, 2004a).  Environmental 
exposures, such as vinyl chloride, aspartame (a sugar substitute), and electromagnetic fields, 
have been suggested as risk factors for brain cancer, but the evidence to support these 
associations is inconsistent (ACS, 2004a).  Please refer to Appendix C for further information on 
brain cancer. 
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Available case information from the MCR was evaluated for individuals diagnosed with this 
cancer type from 1995-present.  The information reviewed included date of diagnosis, age at 
diagnosis, histology (cancer cell type), and previous cancer diagnoses.  However, information 
about personal risk factors that may also influence the development of brain cancer (e.g., family 
history and heredity) are not collected by the MCR or any other readily accessible source, and 
therefore, could not be evaluated in this investigation. 
 
1. Age at Diagnosis 
After a peak in childhood (generally under 10 years of age), the risk of developing brain cancer 
increases with age from age 25 to age 75.  Brain cancers occur with different frequencies among 
the various age-groups, and most brain cancer occurs more frequently in older populations (i.e., 
those over 50 years of age) (Ries et al, 2004).  Statewide, cancers of the brain and central 
nervous system (CNS) are the second most common type of cancer in children. 
 
From 1995-present, the average age at diagnosis among the 20 individuals in Weston with brain 
cancer was 58, with a range of 6 to 92 years of age at diagnosis.  Two children (i.e., ages 0-19) 
from 1995-2001 and one child from 2002-present were diagnosed with brain cancer and reported 
to the MCR.  The majority of individuals (70%, n = 14) were 50 years of age or older at the time 
of diagnosis.  Females in Weston (who experienced a statistically significant elevation in the 
incidence of brain cancer during 1995-2001) had an average age of 49 at diagnosis with a range 
of 6 to 84 years; half of the females diagnosed from 1995-present (six of 12) were over the age 
of 50 at the time of diagnosis.  
 
From 1995-present, the average age of diagnosis among the 11 individuals in Wayland 
diagnosed with brain cancer was 45, with a range of 3 to 77 years of age at diagnosis.  During 
this time period, two children (i.e., ages 0-19) were diagnosed with brain cancer.  Thirty-six 
percent (n = 4) were 50 years of age or older at the time of diagnosis.   
 
2. Histology 
The most common primary brain tumors are gliomas. Gliomas are a general classification of 
malignant tumors that include a variety of types, named for the cells from which they arise: 
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astrocytomas, oligodendrogliomas, and ependymomas.  In addition to these main types, there are 
a number of rare brain tumors, including medulloblastomas, which develop from the primitive 
stem cells of the cerebellum and are most often seen in children.  In adults, the most frequent 
types of brain tumors are astrocytic tumors (mainly astrocytomas and glioblastoma multiforme).  
About half of all childhood brain tumors are astrocytomas and 25% are medulloblastomas (ACS, 
2004b).  
 
Of the 20 individuals from Weston reported to the MCR with brain cancer during 1995-present, 
approximately 85% (n = 17) were diagnosed with a glioma, the most common type of brain 
cancer.  Other histology types included a medulloblastoma, a germinoma, and a general 
neoplasm of the brain.  Each of the three children in Weston diagnosed with brain cancer during 
this time period had a different histology which included a pilocytic astrocytoma, a 
medulloblastoma and a germinoma.  Of the 12 females diagnosed with brain cancer in Weston 
during this time period, 75% (n = 9) were diagnosed with a glioma.   
 
All of the 11 individuals in Wayland were diagnosed with a glioma.  Both children in Wayland 
reported to the MCR with a diagnosis of brain cancer during 1995-present were diagnosed with 
the astrocytoma sub-type of glioma. 
 
Our review of the various histologies, for all of the individuals diagnosed with brain cancer, 
revealed that for both children and adults in both communities, no unusual patterns of histology 
were observed. 
 
3. Previous Cancer Diagnosis 
One of the well established risk factors (and only established environmental risk factor) for brain 
tumors (either cancerous or non-cancerous) is high-dose exposure to ionizing radiation (i.e., x-
rays and gamma rays) (Preston-Martin & Mack, 1996).  Most radiation-induced brain tumors are 
caused by radiation to the head from the treatment of other cancers (ACS, 2004a).  Review of 
specific patient information from the MCR for the 1995-present time period identified two 
individuals (both females and residents of CT 3672) in Weston and one individual (male) in 
Wayland diagnosed with brain cancer who had been previously diagnosed with cancer.  These 
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three patients may have received treatment that could have contributed to their subsequent 
diagnosis of brain cancer.  However, it is not possible to determine whether these individuals 
actually received radiation therapy for their cancer. 
 
IV. Discussion and Conclusions 
According to statistics from the American Cancer Society, cancer is the second leading cause of 
death in Massachusetts and the United States.  Not only will one out of three people develop 
cancer in their lifetime, but cancer will affect three out of every four families.  For this reason, 
cancers often appear to occur in “clusters,” and it is understandable that someone may perceive 
that there are an unusually high number of cancer cases in their surrounding neighborhoods or 
towns.  Upon close examination, many of these “clusters” are not unusual increases, as first 
thought, but are related to such factors as local population density, variations in reporting or 
chance fluctuations in occurrence.  In other instances, the “cluster” in question includes a high 
concentration of individuals who possess related behaviors or risk factors for cancer.  Some, 
however, are unusual; that is, they represent a true excess of cancer in a workplace, a 
community, or among a subgroup of people.  A suspected cluster is more likely to be a true 
cancer cluster if it involves a large number of cases of one type of cancer diagnosed in a 
relatively short time period rather than several different types diagnosed over a long period of 
time (i.e., 20 years), a rare type of cancer rather than common types, and a large number of cases 
diagnosed among individuals in age groups not usually affected by that cancer.  These types of 
clusters may warrant further public health investigation. 
 
During the 1995-2001 period, two children (ages 0-19) were diagnosed with brain cancer in 
Weston while approximately one childhood diagnosis would have been expected.  The two 
children lived in different census tracts.  When reviewing data from the MCR available for 2002-
present, one additional child in Weston was reported with a diagnosis of brain cancer.  During 
the 1995-2001 time period, one child was diagnosed with brain cancer in Wayland, which is 
what would have been expected based on the statewide brain cancer experience for children.  
Also, when reviewing MCR data for 2002-present for Wayland, one additional child was 
reported with a diagnosis of brain cancer.  A statistically significant elevation in the overall 
incidence of brain cancer (adults and children) was observed in the town of Weston over this 
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seven-year period.  This elevation was due to an excess among females living in the town, with 
ten observed diagnoses versus approximately three diagnoses expected (SIR = 364, 95% CI = 
174-670), and more specifically, among females in CT 3672 with seven observed diagnoses 
versus approximately two cases expected (SIR = 387, 95% CI = 155-797).  As discussed, two of 
these individuals had a previous diagnosis of cancer and if radiation treatment occurred it may 
have contributed to their brain cancer diagnosis.  In Wayland, the incidence of brain cancer from 
1995-2001 was slightly elevated (nine diagnoses observed versus seven diagnoses expected), but 
the elevation was not statistically significant.  
 
CAP reviewed available case information and the temporal and geographic patterns of diagnoses 
for children and adults in these two communities.  Based on what is reported in the medical 
literature on the known or established cancer incidence patterns for brain cancer, specifically age 
at diagnosis and the various histologies for brain cancer, our review of available information 
reported to the MCR for the individuals in Weston and Wayland did not show any unusual 
patterns with respect to age at diagnosis or histologies.  Similarly, no temporal or geographic 
clustering was noted among the cases.   
 
Finally, it is important to mention conclusions reached from the previous Health Consultation 
released by the CAP in February 2001 entitled Assessment of Cancer Incidence and Exposure 
Opportunities from the Former Dow Chemical Site in Wayland, MA 1982-1994, 1995 (Appendix 
D).  Review of available environmental sampling information concluded that “the site posed no 
public health hazard to the general public” (MDPH, 2001).  The evaluation of exposure pathways 
from contaminants present at the Dow site in that report did not indicate that significant 
exposures were likely to have occurred to local residents.  Although the causes of brain cancer 
are still unknown, based on the information reviewed in this report, it does not appear that a 
common factor (environmental or non-environmental) played a primary role in the development 
of brain cancer in Weston and Wayland.   
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V. Recommendations 
Based on the information reviewed in this report, no further evaluation of brain cancer in Weston 
and Wayland is recommended at this time.  However, the CEH will monitor the incidence of 
brain cancer among females residing in Weston as new data become available through the MCR. 
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Appendix A – Coding Definitions of Cancer Site/Type 
 
Appendix A: 
Coding Definitions of Cancer Site/Type* 
  ICD-O-1 and Other  
Pre-ICD-O-2 Codes 
ICD-O-2 Codes ICD-O-3 Codes 
Cancer Site / Type 
Site code Histology code Site code Histology code Site code Histology code 
Bladder 188.0-188.9 except 9590-9980 C67.0-C67.9 except 9590-9989 C67.0-C67.9 except 9590-9989 
Brain & Central 
Nervous System (CNS) 
191.0-192.9 
 See Table 1 
below 
C70.0-C72.9 See ICD-O codes 
in Table 1 below 
C70.0-C72.9 
except 9590-
9989 
Breast 174.0-174.9, 
175.9 
except 9590-9980 C50.0-C50.9 except 9590-9989 C50.0-C50.9 except 9590-9989 
Cervix Uteri 180.0-180.9 except 9590-9980 C53.0-C53.9 except 9590-9989 C53.0-C53.9 except 9590-9989 
Colon & Rectum 153.0-153.9, 
154.0, 154.1, 
154.9, 159.0 
except 9590-9980 C18.0-C18.9, 
C19.9, C20.9, 
C26.0 
except 9590-9989 C18.0-C18.9, 
C19.9, C20.9, 
C26.0 
except 9590-9989 
Corpus Uteri & 
Uterus, NOS 
179.9, 182.0- 
182.9 
except 9590-9980 C54.0-C54.9, 
C55.9 
except 9590-9989 C54.0-C54.9, 
C55.9 
except 9590-9989 
Esophagus 150.0-150.9 except 9590-9980 C15.0-C15.9 except 9590-9989 C15.0-C15.9 except 9590-9989 
Hodgkin’s Disease 140.0-199.9   includes O9650-
O9667, P9653-
P9683, B9653-
B9658 
C00.00-C80.9 includes 9650-
9667 
C00.00-C80.9 includes 9650-
9667 
Kidney &  
Renal Pelvis 
189.0, 189.1 except 9590-9980 C64.9, C65.9 
 
except 9590-9989 C64.9, C65.9 
 
except 9590-9989 
Larynx 161.0-161.9 except 9590-9980 C32.0-C32.9 except 9590-9989 C32.0-C32.9 except 9590-9989 
Leukemia 
 
 
 
 
140.0-199.9 
 
includes O9800-
O9943, O9951, 
P9803-P9943, 
B9803-B9943 
1. C00.0-C80.9 
 
 
AND
2. C42.0, C42.1, 
C42.4 
1. includes 9800-
9822, 9824-9826, 
9828-9941 
 
2. includes 9823, 
9827 
1. C00.0-C80.9 
 
 
 
AND 
2. C42.0, C42.1, 
C42.4 
1. includes 9733, 
9742, 9800-9820, 
9826, 9831-9948, 
9963-9964 
 
2. includes 9823, 
9827 
Liver 
 
155.0  except 9590-9980 C22.0
 
except 9590-9989 C22.0 
 
except 9590-9989 
Lung & Bronchus 
 
162.2-162.9 
 
except 9050-9053, 
9590-9980 
C34.0-C34.9 
 
except 9590-9989 C34.0-C34.9 
 
except 9590-9989 
Appendix A (continued) 
  ICD-O-1 and Other  
Pre-ICD-O-2 Codes 
ICD-O-2 Codes ICD-O-3 Codes 
Cancer Site / Type 
Site code Histology code Site code Histology code Site code Histology code 
Melanoma 173.0-173.9   includes O8720-
O8790, B8723-
B8783, P8723-
P8783 
C44.0-C44.9 includes 8720-
8790 
C44.0-C44.9 includes 8720-
8790 
Multiple Myeloma 140.0-199.9      includes O9730,
O9731, O9732, 
P9733, B9733 
C00.0-C80.9 includes 9731,
9732 
C00.0-C80.9 includes 9731,
9732, 9734 
Non-Hodgkin's 
Lymphoma (NHL) 
 
 
 
 
 
140.0-199.9 
 
includes O9590-
O9642, O9670-
O9710, O9750, 
P9593-P9643, 
P9693-P9713, 
P9753, B9593-
B9643, B9703 
1. C00.0-C80.9 
 
AND
2. All sites 
except C42.0, 
C42.1, C42.4 
1. includes 9590-
9595, 9670-9717 
 
2. includes 9823, 
9827 
1. C00.0-C80.9 
 
AND 
2. All sites 
except C42.0, 
C42.1, C42.4 
1. includes 9590-
9596, 9670-9729 
 
2. includes 9823, 
9827 
Oral Cavity & 
Pharynx 
140.0-149.9 except 9590-9980 C00.0-C14.8 except 9590-9989 C00.0-C14.8 except 9590-9989 
Ovary 183.0 except 9590-9980 C56.9 except 9590-9989 C56.9 except 9590-9989 
Pancreas 157.0-157.9 except 9590-9980 C25.0-C25.9 except 9590-9989 C25.0-C25.9 except 9590-9989 
Prostate 185.0, 185.9 except 9590-9980 C61.9 except 9590-9989 C61.9 except 9590-9989 
Stomach 151.0-151.9 except 9590-9980 C16.0-C16.9 except 9590-9989 C16.0-C16.9 except 9590-9989 
Testis 186.0-186.9 except 9590-9980 C62.0-C62.9 except 9590-9989 C62.0-C62.9 except 9590-9989 
Thyroid 193.9 except 9590-9980 C73.9 except 9590-9989 C73.9 except 9590-9989 
*Note:  Includes invasive tumors only, selected by excluding in situ stages J0, S0, TTISNXM0, TTANXMX, TTANXM0, TTAN0MX, 
TTISN0M0, TTISNXMX, TTISN0MX, TTISN0M0, TTIN0M0, TTIN0MX, TTINXM0, and TTINXMX (1982-1994 data) or by specifying 
behavior code (1995-present data). 
Table 1: Histology codes for Brain and Central Nervous System  (pre-ICD-O-3) 
ICD-O   O 9370, 9380, 9381, 9382, 9390, 9391, 9392, 9400, 9401, 9403, 9410, 9411, 9420, 9421, 9422, 9423, 9424, 9430, 9440, 9441, 9442, 
9443, 9450, 9451, 9460, 9470, 9471, 9472, 9473, 9480, 9481, 9490, 9500, 9501, 9502, 9503, 9530, 9539, 9540, 9560, 9561. 
SNOP  P 9363, 9383, 9393, 9403, 9413, 9423, 9433, 9443, 9453, 9463, 9473, 9483, 9493, 9503, 9533, 9543, 9563. 
HLTHSTT  B 9383, 9393, 9403, 9433, 9443, 9453, 9463, 9473, 9483, 9493, 9503, 9530, 9533, 9537, 9543, 9563. 
Source: Massachusetts Department of Public Health, Bureau of Environmental Health Assessment (December 1998) 
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Appendix B – Explanation of a Standardized Incidence Ratio (SIR)  
and 95% Confidence Interval 
 
Appendix B 
 
Explanation of a Standardized Incidence Ratio (SIR) 
And 95% Confidence Interval 
 
 In order to evaluate cancer incidence a statistic known as a standardized incidence ratio 
(SIR) was calculated for each cancer type.  An SIR is an estimate of the occurrence of cancer in a 
population relative to what might be expected if the population had the same cancer experience 
as some larger comparison population designated as “normal” or average.  Usually, the state as a 
whole is selected to be the comparison population.  Using the state of Massachusetts as a 
comparison population provides a stable population base for the calculation of incidence rates.  
As a result of the instability of incidence rates based on small numbers of cases, SIRs were not 
calculated when fewer than five cases were observed.  
 
Specifically, an SIR is the ratio of the observed number of cancer cases to the expected 
number of cases multiplied by 100.  An SIR of 100 indicates that the number of cancer cases 
observed in the population evaluated is equal to the number of cancer cases expected in the 
comparison or “normal” population.  An SIR greater than 100 indicates that more cancer cases 
occurred than expected and an SIR less than 100 indicates that fewer cancer cases occurred than 
expected.  Accordingly, an SIR of 150 is interpreted as 50% more cases than the expected 
number; an SIR of 90 indicates 10% fewer cases than expected. 
 
Caution should be exercised, however, when interpreting an SIR.  The interpretation of 
an SIR depends on both the size and the stability of the SIR.  Two SIRs can have the same size 
but not the same stability.  For example, an SIR of 150 based on 4 expected cases and 6 observed 
cases indicates a 50% excess in cancer, but the excess is actually only two cases.  Conversely, an 
SIR of 150 based on 400 expected cases and 600 observed cases represents the same 50% excess 
in cancer, but because the SIR is based upon a greater number of cases, the estimate is more 
stable.  It is very unlikely that 200 excess cases of cancer would occur by chance alone. 
 
 To determine if the observed number of cases is significantly different from the expected 
number or if the difference may be due solely to chance, a 95% confidence interval (CI) was 
calculated for each SIR.  A 95% CI assesses the magnitude and stability of an SIR.  Specifically, 
a 95% CI is the range of estimated SIR values that has a 95% probability of including the true 
SIR for the population.  If the 95% CI range does not include the value 100, then the study 
population is significantly different from the comparison or “normal” population.  “Significantly 
different” means there is less than 5% percent chance that the observed difference is the result of 
random fluctuation in the number of observed cancer cases. 
 
 For example, if a confidence interval does not include 100 and the interval is above 100 
(e.g., 105-130), then there is statistically significant excess in the number of cancer cases.  
Similarly, if the confidence interval does not include 100 and the interval is below 100 (e.g., 45-
96), then the number of cancer cases is statistically significantly lower than expected.  If the 
confidence interval range includes 100, then the true SIR may be 100, and it cannot be concluded 
with sufficient confidence that the observed number of cases is not the result of chance and 
reflects a real cancer increase or decrease.  Statistical significance is not assessed when fewer 
than five cases are observed. 
 
Source: Massachusetts Department of Public Health, Bureau of Environmental Health Assessment (December 
1998) 
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In addition to the range of the estimates contained in the confidence interval, the width of the 
confidence interval also reflects the stability of the SIR estimate.  For example, a narrow 
confidence interval (e.g., 103--115) allows a fair level of certainty that the calculated SIR is close 
to the true SIR for the population.  A wide interval (e.g., 85--450) leaves considerable doubt 
about the true SIR, which could be much lower than or much higher than the calculated SIR.  
This would indicate an unstable statistic. 
 
Source: Massachusetts Department of Public Health, Bureau of Environmental Health Assessment (December 
1998) 
  
 
 
 
 
 
 
 
 
 
 
 
Appendix C – Risk Factor Summary for Brain Cancer 
 
Risk Factor Information for Brain and Central Nervous System Cancers 
 
Brain and central nervous system (CNS) tumors can be either malignant (cancerous) or benign 
(non-cancerous).  Primary brain tumors (i.e., brain cancer) comprise two main types: gliomas 
and malignant meningiomas.  Gliomas are a general classification of malignant tumors that 
include a variety of types, named for the cells from which they arise: astrocytomas, 
oligodendrogliomas, and ependymomas.  Meningiomas arise from the meninges, which are 
tissues that surround the outer part of the spinal cord and brain.  Although meningiomas are not 
technically brain tumors, as they occur outside of the brain, they account for about 50% of all 
reported primary brain and spinal cord tumors.  The majority of meningiomas (about 85%) are 
benign and can be cured by surgery.  Therefore, approximately 7.5% of brain and CNS tumors 
are malignant meningiomas.  In addition to these main types, there are a number of rare brain 
tumors, including medulloblastomas, which develop from the primitive stem cells of the 
cerebellum and are most often seen in children.  Also, the brain is a site where both primary and 
secondary malignant tumors can arise; secondary brain tumors generally originate elsewhere in 
the body and then metastasize, or spread, to the brain (ACS, 1999a).  The American Cancer 
Society estimates that 18,500 Americans (10,620 men and 7,880 women) will be diagnosed with 
primary brain cancer (including cancers of the central nervous system, or spinal cord) and 
approximately 12,760 people (7,280 men and 5,480 women) will die from this disease in 2005 
(ACS, 2005). 
 
Brain and spinal cord cancers account for over 20% of all cancer types diagnosed among 
children aged 0-14 (ACS, 2005).  About half of all childhood brain tumors are astrocytomas and 
25% are medulloblastomas (ACS, 1999b).  After a peak in childhood (generally under 10 years 
of age), the risk of brain cancer increases with age from age 25 to age 75.  In adults, the most 
frequent types of brain tumors are astrocytic tumors (mainly astrocytomas and glioblastoma 
multiforme).  Incidence rates are higher in males than in females for all types.  In general, the 
highest rates of brain and nervous system cancer tend to occur in whites.   However, this varies 
somewhat by type; the incidence of gliomas is lower among black men and women than whites, 
but for meningiomas, the reverse is true (Preston-Martin and Mack, 1996). 
 
Despite numerous scientific and medical investigations, and analyses, the causes of brain cancer 
are still largely unknown.  Among the possible risk factors investigated in relation to this type of 
cancer are ionizing radiation, electromagnetic fields, occupational exposures, exposure to N-
nitroso compounds, head trauma, and genetic disorders. 
 
The most established risk factor (and only established environmental risk factor) for brain tumors 
(either cancerous or non-cancerous) is high-dose exposure to ionizing radiation (i.e., x-rays and 
gamma rays).  Most radiation-induced brain tumors are caused by radiation to the head from the 
treatment of other cancers (ACS, 1999a).  Meningiomas are the most common type of tumors 
that occur from this type of exposure, but gliomas may also occur (Preston-Martin and Mack, 
1996).  Among adults, the risk of developing meningiomas has been associated with full-mouth 
dental x-rays taken decades ago when radiation doses were higher than today.  Although the 
relationship between low-dose radiation exposure and increased risk of brain tumors has been 
debated in several studies, prenatal exposure from diagnostic x-rays has been related to an 
increase in childhood brain tumors (Preston-Martin and Mack, 1996). 
 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health 
March, 2005 
Risk Factor Information for Brain and Central Nervous System Cancers 
 
In recent years, there has been increasing public concern and scientific interest regarding the 
relationship of electromagnetic fields (EMF) to brain cancer.  However, results from recent 
epidemiological investigations provide little or no evidence of an association between residential 
EMF exposure (e.g., from power lines and home appliances) and brain tumors (Kheifets, 2001).  
Studies also suggest that the use of handheld cellular telephones is not associated with an 
increased risk of primary brain cancer (Muscat et al., 2000).  However, given the relatively 
recent use of cellular phones, evidence is preliminary and few studies have been conducted. 
 
Other environmental factors such as exposure to vinyl chloride (used in the manufacturing of 
some plastics) and aspartame (a sugar substitute) have been suggested as possible risk factors for 
brain cancer but no conclusive evidence exists implicating these factors (ACS, 1999a).  Although 
some occupational studies have suggested that electrical and electric utility workers may be at a 
slightly increased risk of brain cancer, these studies have important limitations, such as exposure 
misclassifications and a lack of dose-response relationships (Kheifets, 2001).  Some researchers 
have also reported an increased risk of brain tumors in adults among veterinarians and farmers.  
Exposures to farm animals and pets have been considered as possible risk factors because of 
their association with bacteria, pesticides, solvents, and certain animal oncogenic (cancer-
related) viruses (Yeni-Komshian and Holly, 2000).  However, the relationship between farm life 
and brain cancer remains controversial. 
 
Recent reports have proposed a link between occupational exposure to lead and brain cancer risk, 
but further analytic studies are warranted to test this hypothesis (Cocco et al., 1998).  In a recent 
case-control study, the concentrations of metal and non-metal compounds in brain biopsies from 
patients with primary brain tumors were compared to results from an analysis of tumor-free brain 
tissue.  Statistically significant associations were observed between the presence of brain tumors 
and the concentrations of silicon, magnesium, and calcium (Hadfield et al., 1998).  However, 
further research using a larger sample size is needed to determine whether exposure to these 
elements plays a role in the development of brain cancer.  Other occupations that may be 
associated with elevated risks include workers in certain health professions (e.g., pathologists 
and physicians), agricultural workers, workers in the nuclear industry, and workers in the rubber 
industry, although specific exposures have not been established (Preston-Martin and Mack, 
1996).  Studies investigating the possible association between occupational exposure of parents 
(in particular, paper or pulp-mill, aircraft, rubber, metal, construction, and electric workers) and 
the onset of brain tumors in their children have provided inconsistent results (Preston-Martin and 
Mack, 1996). 
 
The association between the development of brain cancer and nitrites and other N-nitroso 
compounds, among the most potent of carcinogens, has been heavily researched.  N-nitroso 
compounds have been found in tobacco smoke, cosmetics, automobile interiors, and cured meats.  
A recent study concluded that an increased risk of pediatric brain tumor may be associated with 
high levels of nitrite intake from maternal cured meat consumption during pregnancy (Pogoda 
and Preston-Martin, 2001).  However, the role of nitrites and cured meats in the development of 
brain cancer remains controversial (Blot et al., 1999; Bunin, 2000).  Because most people have 
continuous, low level exposure to N-nitroso compounds throughout their lives, further studies, 
especially cohort studies, are needed to determine if this exposure leads to an increased risk of 
brain tumors (Preston-Martin, 1996). 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health 
March, 2005 
Risk Factor Information for Brain and Central Nervous System Cancers 
 
 
Injury to the head has been suggested as a possible risk factor for later development of brain 
tumors but most researchers agree that there is no conclusive evidence for an association (ACS, 
1999b).  Head trauma is most strongly associated with the development of meningiomas 
compared with other types of brain tumor.  Several studies have found an increased risk in 
women with histories of head trauma; in men who boxed; and in men with a previous history of 
head injuries.  Gliomas are the most common type of childhood brain tumor and have been 
positively associated with trauma at birth (e.g., Cesarean section, prolonged labor, and forceps 
delivery).  However, other studies have found no association (Preston-Martin and Mack, 1996). 
 
In addition, rare cases of brain and spinal cord cancer run in some families.  Brain tumors in 
some persons are associated with genetic disorders such as neurofibromatosis types I and II, Li-
Fraumeni syndrome, and tuberous sclerosis.  Neurofibromatosis type I (von Recklinghausen’s 
disease) is the most common inherited cause of brain or spinal cord tumors and occurs in about 
one out of every 3,000 people (Preston-Martin and Mack, 1996).  The disease may be associated 
with optic gliomas or other gliomas of the brain or spinal cord (ACS, 1999b).  Of those afflicted 
with the disease, about 5-10% will develop a central nervous system tumor (Preston-Martin and 
Mack, 1996).  In addition, von Hippell-Lindau disease is associated with an inherited tendency to 
develop blood vessel tumors of the cerebellum (ACS, 1999a).  However, malignant (or 
cancerous) brain tumors are rare in these disorders; inherited syndromes that predispose 
individuals to brain tumors appear to be present in fewer than 5% of brain tumor patients 
(Preston-Martin and Mack, 1996). 
 
Other possible risk factors investigated for brain cancer have included alcohol consumption, use 
of barbiturates, smoking and exposure to second-hand smoke, pesticides, and infectious diseases 
(i.e., tuberculosis and chicken pox).  To date, studies on these risk factors have yielded 
inconclusive results.  Further, the majority of individuals diagnosed with brain cancer have no 
known risk factors (ACS, 1999a). 
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